Accelerate Diagnostics, Inc.
AXDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.02 | 0.02 | 0.42 |
| FCF Yield | -88.34% | -84.30% | -84.48% | -14.87% |
| EV / EBITDA | -2.37 | -1.53 | -1.81 | -6.60 |
| Quality | ||||
| ROIC | -243.30% | -253.42% | -110.41% | -92.37% |
| Gross Margin | 23.12% | 21.15% | 25.90% | -3.23% |
| Cash Conversion Ratio | 0.48 | 0.65 | 0.78 | 0.61 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.83% | 0.78% | 4.53% | 8.22% |
| Free Cash Flow Growth | 40.09% | 16.34% | -2.83% | 7.40% |
| Safety | ||||
| Net Debt / EBITDA | -1.53 | -0.54 | -0.76 | -1.20 |
| Interest Coverage | -2.69 | -6.98 | -16.65 | -4.60 |
| Efficiency | ||||
| Inventory Turnover | 3.15 | 2.87 | 1.82 | 2.40 |
| Cash Conversion Cycle | -17.28 | 22.32 | 95.92 | 164.42 |